News

Mylan gains U.S., Canada rights to proposed generic equivalents of Flixotide and Flovent

BY Michael Johnsen

OXFORD, England  — Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

PSX1001 and PSX1050, which are the first products to emerge from Prosonix’s proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline’s pressurised metered dose inhalers Flixotide and Flovent, respectively. Flixotide and Flovent contain the active ingredient fluticasone propionate, a potent inhaled corticosteroid, and are indicated for the treatment of asthma. 

According to IMS Health, Flixotide and Flovent had global brand sales of approximately $1.3 billion for the 12 months ended Dec. 31, 2013. A first marketing authorisation application for PSX1001 is expected to be submitted in the European Union in 2014.

Under the terms of the licensing agreement, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories. Mylan has marketing rights for PSX1001 and PSX1050 in the U.S., Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States. All other terms of the agreement remain confidential.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Mylan announces launch of generic Lunesta

BY Ryan Chavis

PITTSBURGH — Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form. The drug — which is used for the treatment of insomnia — is the generic version of Lunesta from Sunovion Pharmaceuticals.

Mylan received final approval from the Food and Drug Administration for its abbreviated new drug application. Eszopiclone tablets had sales in the U.S. of approximately $851.8 million for the 12 months ending Dec 31, 2013, according to IMS Health.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Supervalu to open Colorado DC to feed Denver market

BY Michael Johnsen

ST. LOUIS- — Supervalu’s Save-A-Lot on Monday announced plans for a new 140,000-sq.-ft. food distribution center in Aurora, Colo., in June 2014. 

Save-A-Lot currently services its stores in this market out of the company’s distribution center located in Dallas. 

“This project represents a significant investment in Denver and the surrounding markets,” said Ritchie Casteel, president and CEO of Save-A-Lot. “We are excited about the opportunity to more efficiently serve our current stores as well as opening up the area for growth possibilities in the future.”

There are 15 Save-A-Lot stores in the Denver Market. The new distribution center will help support the company’s growth plans in Denver and the surrounding states, the company stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?